# Droplet Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/droplet-biosciences

- Industry: Biotechnology
- Headquarters: Melrose, US
- Website: www.dropletbiosci.com
- Total disclosed funding: $8M
- Latest round: Seed (Mar 16, 2023)
- Investors on record: 1

## About

Based in Massachusetts, US, and co-founded by Theresa Tribble (CEO) and Stan Lapidus along with the scientific co-founders Jose P. Zevallos and Aadel Chaudhuri in 2021, Droplet Biosciences, Inc operates as a biotechnology platform that engages in diagnosing cancer using bioinformatics. In March 2023, the firm raised USD 8 million in seed funding led by investor The Engine.

The company as of April 2023, has developed a non-invasive liquid biopsy technique called Lymph to identify the risk of recurrence of cancer enabling medical practitioners to make post-operative treatment decisions and plans for every individual patient. Under this technique, lymphatic fluid is collected from surgical drain fluid after tumor resection or surgery, and the fluid is rich in T-cells, proteins, and other biomarkers, assesses metastatic risk, and offers insights into the body’s immune response to cancer. 

The company plans to utilize its March 2023 funding to establish proof of concept for its Lymph technology.

## Funding rounds

- Seed, Mar 16, 2023, $8M — Engine Ventures

## Investors

- Engine Ventures (https://capitalatlas.ai/funds/engine-ventures) — Seed